Takeda tests new concentrated antibody shot against existing treatment
NCT ID NCT06895967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial enrolled 30 healthy adults aged 18-50 to compare how the body absorbs and clears two antibody treatments given as a single injection under the skin: TAK-881 and HyQvia. Participants stayed at the clinic for 8 days and had follow-up visits up to Day 85. The study focuses on drug levels in the blood, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-881 (immune globulin with hyaluronidase) and HyQvia (immune globulin with hyaluronidase)
- What this could lead to
- If successful, this could help develop a more concentrated antibody treatment that is easier to inject under the skin.
- What could go wrong
- This is an early-phase trial in healthy volunteers, not patients. It only measures drug levels in the body, not whether the drug works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion
Tempe, Arizona, 85283, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults